Showing 3311-3320 of 5685 results for "".
- Forecasting the New Normal: Experts Across Eye Care Discuss COVID-19’s Impacthttps://modernod.com/news/covid-19-forecasting-the-new-normal/2477626/In a recent episode of Ophthalmology Off the Grid, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, were joined by Iqbal Ike K. Ahmed, MD, FRCSC; John Kitchens, MD; and Justin Schweitzer, OD, to discuss COVID-19’s impact across eye care and share their predictions for how the current
- The Tests That Could Reopen the Country: How They Workhttps://modernod.com/news/the-tests-that-could-reopen-the-country-how-they-work/2477614/After weeks of sheltering in place, Americans are asking how soon we can return to a more normal life outside our homes. Much of the answer might be in a test. The first phase of testing has been about determining who has COVID-19. The next phase will be about who had it – or may
- HealthVerity Patient Confidence Index Aims to Become Bellwether Measure of Impact to Non-COVID-19 Patients and Physicianshttps://modernod.com/news/healthverity-patient-confidence-index-aims-to-become-bellwether-measure-of-impact-to-non-covid-19-patients-and-physicians/2477590/HealthVerity, a provider of privacy-protected data exchange for pharmaceutical manufacturers and insurers, announced the launch of the HealthVerity Patient Confidence Index, or HVPCI, and reported the first national benchmark score of 68. Indexed against a pre-pandemic score of 100, this level is
- I’m Laid Off/Furloughed/Fired, Now What?https://modernod.com/news/im-laid-off-furloughed-fired-now-what/2477584/
- AstraZeneca to Study BTK Inhibitor Calquence as Treatment for Cytokine Storm Associated With COVID-19 Infectionhttps://modernod.com/news/astrazeneca-to-study-btk-inhibitor-calquence-as-treatment-for-cytokine-storm-associated-with-covid-19-infection/2477575/AstraZeneca announced that it will investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of the cytokine storm associated with COVID-19 infection in severely ill patients. The company noted that the design of the CALAVI study is based on “strong scientifi
- Retina Industry Giants Temporarily Extend Payment Termshttps://modernod.com/news/retina-industry-giants-temporarily-extend-payment-terms/2477512/Genentech, Regeneron, Allergan, and Novartis are extending payment terms in response to the COVID-19 crisis. George Williams, MD, discussed the terms of extended payment by Genentech and Regeneron on a recent episode of New Retina Radio, and the details were confirmed by statements from th
- Zeiss Releases Company Update on COVID-19 Pandemichttps://modernod.com/news/zeiss-releases-company-update-on-covid-19-pandemic/2477475/In response to the spread of the novel coronavirus, Zeiss released a statement stating that it has developed comprehensive measures to protect employees and maintain smart business continuity. The statement reads: “In light of the current situation created by the COVID-19 pand
- FDA Authorizes Hand-Held COVID-19 Diagnostic Testhttps://modernod.com/news/fda-authorizes-hand-held-covid-19-diagnostic-test/2477452/In response to the coronavirus crisis, we’ve seen COVID-19 diagnostics quickly evolve from early, multistep kits to high-throughput versions to fast point-of-care tests, all in just a few weeks. Now, the FDA has granted an emergency authorization to a device that fits in the palm of you
- Zeiss Medical Technology Launches New Website “Zeiss MED Support Now”https://modernod.com/news/zeiss-medical-technology-launches-new-website-zeiss-med-support-now/2477453/Zeiss Medical Technology has launched a new website “
- FDA Clamps Down On At-Home Coronavirus Testing, Citing Fake Products and Bad Actorshttps://modernod.com/news/fda-clamps-down-on-at-home-coronavirus-testing-citing-fake-products-and-bad-actors/2477444/After telling companies, laboratories and state health departments to move forward with emergency coronavirus testing without federal oversight or approval, the FDA is now working to rein in the ones it describes as going too far, according to a <